TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06534437: An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Sponsor: Ryvu Therapeutics SA · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 178 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,207,200

Rescue Site Savings

+$4,758,600

Unlock Full NCT06534437 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06534437 Rescue Dossier →